Conversely, miR-320 knockdown decreased lipogenic gene FAS by enhancing LEPR in the cytoplasm and downregulating CD36 transcription in the nucleus, which provided a potential therapeutic target for treating NAFLD in the future. The gene discussed is LEPR; the disease is metabolic dysfunction-associated steatotic liver disease.